384 related articles for article (PubMed ID: 29259984)
1. mTOR-Dependent Cell Proliferation in the Brain.
Ryskalin L; Lazzeri G; Flaibani M; Biagioni F; Gambardella S; Frati A; Fornai F
Biomed Res Int; 2017; 2017():7082696. PubMed ID: 29259984
[TBL] [Abstract][Full Text] [Related]
2. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
3. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
[TBL] [Abstract][Full Text] [Related]
4. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
5. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
[TBL] [Abstract][Full Text] [Related]
6. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
[TBL] [Abstract][Full Text] [Related]
7. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
8. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
9. Nitidine chloride inhibits the malignant behavior of human glioblastoma cells by targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Wang J; Qi Q; Huang B; Chen A; Li X; Wang J
Oncol Rep; 2016 Oct; 36(4):2160-8. PubMed ID: 27498786
[TBL] [Abstract][Full Text] [Related]
10. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.
Li S; Guo W; Gao Y; Liu Y
Tumour Biol; 2015 Apr; 36(4):2607-12. PubMed ID: 25431263
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
[TBL] [Abstract][Full Text] [Related]
13. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
16. Targeting the AKT pathway in glioblastoma.
McDowell KA; Riggins GJ; Gallia GL
Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
[TBL] [Abstract][Full Text] [Related]
17. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways.
Aeder SE; Martin PM; Soh JW; Hussaini IM
Oncogene; 2004 Dec; 23(56):9062-9. PubMed ID: 15489897
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
19. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
[TBL] [Abstract][Full Text] [Related]
20. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
